Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
Tóm tắt
The introduction in clinical practice of pharmaceutical products known as biosimilars, as part of a more complex series of progress in the field of biological drugs, represents an excellent therapeutic resource. A biosimilar drug is a biological/biotechnological drug that is highly similar to an approved reference biologic product. Given their complexity, biosimilars require attention and a continued vigilance to ensure appropriate use, especially in cancer therapy. There is the urgent need, both at Italian and European levels, of clear and more comprehensive guidelines to elucidate the open questions. Probably, the acquisition of new data, obtained from larger samples of patients than those used in the pre-approval studies and with extremely variable clinical conditions, will allow clarifying the extent to which biosimilar drugs are similar in safety and efficacy to their biologic reference drug. The aims of this article are to provide health professionals with basic, but essential information about biosimilars, and to identify current critical points and future perspectives for clinical practice, cancer care, regulatory aspects, and pharmacovigilance.
Tài liệu tham khảo
European Medicines Agency. Guideline on similar biological medicinal products. London. 2005. http://emea.europa.eu/pdfs/human/biosimilar/043704en.pdf. Accessed 13 July 2016.
Decreto Legislativo 10 febbraio 2005, n. 30. Codice della proprietà industriale, a norma dell’articolo 15 della legge 12 dicembre 2002, n. 273.Camera dei Deputati. 2005. http://www.camera.it/parlam/leggi/deleghe/05030dl.htm. Accessed 16 Apr 2016.
European Commission. Regolamento (CEE) n. 1768/92 del Consiglio, del 18 giugno 1992, sull’istituzione di un certificato protettivo complementare per i medicinali. 1992. http://eur-lex.europa.eu/eli/reg/1992/1768/oj. Accessed 14 Apr 2016.
Baldo P, De Paoli P. Pharmacovigilance in oncology: evaluation of current practice and future perspectives: pharmacovigilance in oncology and current practice. J Eval Clin Pract. 2014;20(5):559–69.
European Generic Medicines Association. Factors supporting a sustainable european biosimilar medicines market. Medicines for Europe. 2014. http://www.medicinesforeurope.com/?s=Factors+supporting+a+sustainable+european+biosimilar+medicines+market. Accessed 26 Apr 2016.
Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. European Medicines Agency. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. Accessed 26 Apr 2016.
Kathmann W. Biosimilars—Potenziale, Risiken und offene Fragen. Aktuelle Rheumatologie. 2014;39(02):80–81. https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0034-1376214. Accessed 26 Apr 2016.
Associazione Italiana di Oncologia Medica. Farmaci biotecnologici e biosimilari. La rivoluzione dei biotech: dalle eritropoietine agli anticorpi monoclonali in oncologia. Associazione Italiana di Oncologia Medica. 2013. http://bio-similari.it/wp-content/uploads/2014/04/2013_AIOM-Farmaci_biotecnologici_e_biosimilari11.pdf. Accessed 26 Apr 2016.
Mellstedt H. Anti-neoplastic biosimilars—the same rules as for cytotoxic generics cannot be applied. Ann Oncol. 2013;24(Suppl 5):v23–8.
National Cancer Institute (NCI). Targeted cancer therapies. National Cancer Institute. 2014. http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet. Accessed 24 Apr 2016.
European Medicines Agency. Press release: European Medicines Agency recommends approval of first two monoclonal-antibody biosimilar. 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001837.jsp&mid=WC0b01ac058004d5c1. Accessed 04 May 2016.
Kumar R, Singh J. Biosimilar drugs: current status. Int J Appl Basic Med Res. 2014; 4(2): 63–66. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137643/.
Roy PS, John S, Karankal S, Kannan S, Pawaskar P, Gawande, J et al. Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis. Indian J Med Paediatr Oncol. 2013;34(4):292–298. http://www.ncbi.nlm.nih.gov/pubmed/24604960.
Qureshi ZP, Magwood JS, Singh S, Bennet CL. Rituximab and biosimilars-equivalence and reciprocity. Biosimilars. 2013;(3):19–25. http://www.ncbi.nlm.nih.gov/pubmed/24829884.
Agenzia Italiana del Farmaco. L’uso dei Farmaci in Italia. Rapporto nazionale Osmed 2013. 2015. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.655.1281&rep=rep1&type=pdf. Accessed 24 Apr 2016.
Ministero Della Salute. Decreto 4 aprile 2013. Criteri di individuazione degli scaglioni per la negoziazione automatica dei generici e dei biosimilari. Ministero della Salute. 2013. http://www.gazzettaufficiale.it/eli/id/2013/06/06/13A04795/sg. Accessed 24 Apr 2016.
Pani L. Farmaci Biotecnologici e biosimilari: Innovazione e Sostenibilità del sistema pubblico. Agenzia Italiana del Farmaco. 2013. www.senato.it/documenti/repository/…/Prof.%20PANI%20aifa.pdf.
Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. European Medicines Agency. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf.
Bennet CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014;15(13):e594–e605. http://www.ncbi.nlm.nih.gov/pubmed/25456378.
European Commission. What you need to know about biosimilar medicinal products. A consensus information document. European Commission. 2013. http://ec.europa.eu/DocsRoom/documents/8242/attachments/1/translations/en/renditions/native. Accessed 26 Apr 2016.
Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J-J, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469–475. http://www.ncbi.nlm.nih.gov/pubmed/11844847.
European Commission. Direttiva 2010/84/UE del Parlamento Europeo e del Consiglio. European Commission. 2010. http://ec.europa.eu/health/files/eudralex/vol-1/dir_2010_84/dir_2010_84_it.pdf.
Drugs and Therapy Perspectives. Practical Issues and Updates: Improved guidelines will optimize efficacy and minimize adverse effects of biosimilar drugs. Drugs Ther Perspect. 2012 [cited 2016 Apr 27];24(8):24–26. http://link.springer.com/article/10.2165/00042310-200824080-00008.
European Medicines Agency. EMA/244682/2013: Medicines under additional monitoring. European Medcines Agency. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/04/WC500142430.pdf.
Calvo B, Zuñiga L. EU’s new pharmacovigilance legislation: considerations for biosimilars. Drug Saf. 2014;37(1):9–18. http://www.ncbi.nlm.nih.gov/pubmed/24190573.